An Alternate Future

About us


First-in-class therapies to treat neurodegenerative disease

Alterity is developing first-in-class therapies to treat neurodegenerative disease. Our lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.

Our therapies


Quarterly Cash Flow Report

Highlights: Michael J. Fox Foundation grants Alterity $US495K for Parkinson’s disease research evaluation Strengthening profile at investm

Read More

Receive news from Alterity Therapeutics